Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer
Por:
Calvo-Lopez, T, Paz-Cabezas, M, Llovet, P, Ibanez, M, Sastre, J, Alonso-Orduna, V, Vieitez, J, Yubero, A, Vera, R, Asensio-Martinez, E, Garcia-Alfonso, P, Aranda, E, Diaz-Rubio, E and Perez-Villamil, B
Publicada:
1 ene 2022
Resumen:
BACKGROUND: MicroRNAs (miRs) are frequently altered in colorectal cancer (CRC) and can be used as prognostic factors.
OBJECTIVE: To confirm in stage III CRC patients a reported miR signature that was associated to the presence of metastatic disease. To correlate miR expression with microsatellite instability (MSI) and mutations in RAS and BRAF.
METHODS: miR-21, miR-135a, miR-206, miR-335 and miR-Let-7a expression was analyzed by RT-qPCR in 150 patients out of the 329 patients used to analyze MSI and RAS and BRAF mutations. Association with disease free survival (DFS) and overall survival (OS) was analyzed. Data was confirmed by a multivariate analysis.
RESULTS: MiR-21 high expression ( p = 0.034) and miR-335 low expression ( p = 0.0061) were significantly associated with MSI-H. A positive trend (p = 0.0624) between miR-135a high expression and RAS mutations was found. Lower miR-21 expression levels are associated with DFS (HR = 2.654, 95% CI: 1.066-6.605, p = 0.036) and a trend with OS (HR = 2.419, 95% CI: 0.749-7.815, p = 0.140). MiR-21 high expression significantly improves DFS of the poor prognosis group (T4 or N2) (p = 0.03).
CONCLUSIONS: Association of increased expression of miR-21 and better prognosis in the poor prognostic group may be of interest and could be explored in future prospective clinical trials.
Filiaciones:
Calvo-Lopez, T:
Hosp Clin San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Med Oncol Dept, Genom & Microarrays Lab, C Martin Lagos S-N, Madrid 28040, Spain
Paz-Cabezas, M:
Hosp Clin San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Med Oncol Dept, Genom & Microarrays Lab, C Martin Lagos S-N, Madrid 28040, Spain
Llovet, P:
Hosp Clin San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Med Oncol Dept, Genom & Microarrays Lab, C Martin Lagos S-N, Madrid 28040, Spain
Ibanez, M:
Hosp Clin San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Med Oncol Dept, Genom & Microarrays Lab, C Martin Lagos S-N, Madrid 28040, Spain
Sastre, J:
Hosp Clin San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Med Oncol Dept, Genom & Microarrays Lab, C Martin Lagos S-N, Madrid 28040, Spain
Alonso-Orduna, V:
Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon IISA, Zaragoza, Spain
Vieitez, J:
Hosp Univ Cent Asturias, Oviedo, Spain
Yubero, A:
Hosp Clin Univ Lozano Blesa, Zaragoza, Spain
Vera, R:
Complejo Hosp Navarra, Pamplona, Spain
:
Hosp Gen Univ Elche, Alicante, Spain
Garcia-Alfonso, P:
Hosp Univ Gregorio Maranon, Madrid, Spain
Aranda, E:
Hosp Univ Reina Sofia, ISCIII, CIBERONC, IMIBIC, Cordoba, Spain
Diaz-Rubio, E:
Hosp Clin San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Med Oncol Dept, Genom & Microarrays Lab, C Martin Lagos S-N, Madrid 28040, Spain
Perez-Villamil, B:
Hosp Clin San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Med Oncol Dept, Genom & Microarrays Lab, C Martin Lagos S-N, Madrid 28040, Spain
|